TY - JOUR

T1 - Prognostic Value of 18F-FDG-PET Parameters in Patients with Small Cell Lung Cancer

T2 - A Meta-Analysis and Review of Current Literature

AU - Christensen, Tine Nøhr

AU - Andersen, Per Kragh

AU - Langer, Seppo W

AU - Fischer, Barbara Malene Bjerregaard

PY - 2021/1/26

Y1 - 2021/1/26

N2 - Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed®, Cochrane, and Embase® were searched for papers addressing the prognostic value of any PET parameter at any treatment phase with any endpoint in patients with SCLC. Pooled hazard ratios (HRs) were calculated by a random effects model for the prognostic value of the baseline maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV). The qualitative analysis included 38 studies, of these, 19 studies were included in the meta-analyses. The pooled results showed that high baseline MTV was prognostic for overall survival (OS) (HR: 2.83 (95% confidence interval [CI]: 2.00-4.01) and progression-free survival (PFS) (HR: 3.11 (95% CI: 1.99-4.90)). The prognostic value of SUVmax was less pronounced (OS: HR: 1.50 (95% CI: 1.17-1.91); PFS: HR: 1.24 (95% CI: 0.94-1.63)). Baseline MTV is a strong prognosticator for OS and PFS in patients with SCLC. MTV has a prognostic value superior to those of other PET parameters, but whether MTV is superior to other prognosticators of tumor burden needs further investigation.

AB - Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed®, Cochrane, and Embase® were searched for papers addressing the prognostic value of any PET parameter at any treatment phase with any endpoint in patients with SCLC. Pooled hazard ratios (HRs) were calculated by a random effects model for the prognostic value of the baseline maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV). The qualitative analysis included 38 studies, of these, 19 studies were included in the meta-analyses. The pooled results showed that high baseline MTV was prognostic for overall survival (OS) (HR: 2.83 (95% confidence interval [CI]: 2.00-4.01) and progression-free survival (PFS) (HR: 3.11 (95% CI: 1.99-4.90)). The prognostic value of SUVmax was less pronounced (OS: HR: 1.50 (95% CI: 1.17-1.91); PFS: HR: 1.24 (95% CI: 0.94-1.63)). Baseline MTV is a strong prognosticator for OS and PFS in patients with SCLC. MTV has a prognostic value superior to those of other PET parameters, but whether MTV is superior to other prognosticators of tumor burden needs further investigation.

U2 - 10.3390/diagnostics11020174

DO - 10.3390/diagnostics11020174

M3 - Review

C2 - 33530446

VL - 11

JO - Diagnostics

JF - Diagnostics

SN - 2075-4418

IS - 2

M1 - 174

ER -